Biomarkers of Durable Response With Intermittent Therapy With LGX818 and MEK162 Combined Therapy in Patients With BRAF Mutant Metastatic Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 20 Dec 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.